Answers are grounded in this paper and cite their sources.
Objective: To evaluate the efficacy and safety of ondansetron for diarrhea-predominant irritable bowel syndrome (IBS-D) and update the randomized evidence following the 2023 TRITON meta-analysis. Methods: An updated systematic review of randomized controlled trials in adults with Rome III-or IV-defined IBS-D was conducted. Full-text placebo-controlled trials of ≥4 w were eligible. The primary quantitative outcome was study-defined stool-consistency response. Three parallel-group trials were pooled in Review Manager 5.4.1 using a Mantel-Haenszel random-effects risk ratio (RR) with 95% confidence interval (CI). The crossover trial by Garsed et al. was included qualitatively but excluded from the primary independent-arm meta-analysis. Risk of bias was assessed using Cochrane RoB 2. Results: Four randomized controlled trials were included, of which three parallel-group trials involving 304 participants contributed to the meta-analysis. Stool-consistency response occurred in 91/161 participants receiving ondansetron and 53/143 receiving placebo/control. Ondansetron significantly improved stool-consistency response (RR 1.51, 95% CI 1.18–1.93; Z=3.25; P=0.001), with no observed statistical heterogeneity (Tau²=0.00; Chi²=1.13, df=2, P=0.57; I²=0%). Constipation was reported more frequently with ondansetron, although safety outcomes were not pooled because of heterogeneous reporting and study designs. Conclusion: Ondansetron significantly improved study-defined stool-consistency response in adults with IBS-D. Larger trials using standardized contemporary endpoints are warranted.
No takes yet. Share an insight, caveat, or question.
Choudhury et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: